Zyga Announces Highmark, Inc., 4th Largest Blue Cross Blue Shield Insurer, to Expand Positive Coverage of Minimally Invasive SI Joint Fusion
MINNETONKA, Minn., Sept. 18, 2017 /PRNewswire/ -- Zyga Technology, Inc., a medical device company focused on the design, development, and commercialization of minimally invasive devices to treat underserved conditions of the lumbar spine, today announced that Highmark, Inc., the nation's 4th largest Blue Cross and Blue Shield-affiliated insurer, has expanded their positive coverage policy for minimally invasive SI joint fusion effective August 21, 2017. The insurer, which formerly covered only one implant technology, has expanded their policy to now include all FDA-cleared instrumentation for this indication including cages or screws, with or without bone graft.
"We are pleased with Highmark's recent decision to expand their instrumentation coverage for minimally invasive sacroiliac joint fusion," commented Jim Bullock, President and CEO of Zyga Technology. "This change will allow treatment decision making to be at the surgeon and patient level where it belongs."
The Centers for Disease Control and Prevention lists low back pain (LBP) as the second most common cause of disability in U.S. adults[i]. It has been reported that approximately 20 percent of all chronic LBP derives from the sacroiliac joint[ii].
About Zyga Technology, Inc.
Zyga Technology, Inc. is dedicated to the research, development and commercialization of solutions that provide empirical clinical and economic value in the treatment of underserved conditions of the spine. The company is marketing the SImmetry® Sacroiliac Joint Fusion System, a minimally invasive procedure intended for conditions including sacroiliac joint disruptions and degenerative sacroiliitis. The SImmetry System utilizes proven orthopedic principles of decortication, bone grafting and fixation to provide a true SI joint fusion. For more information, visit zyga.com.
[i] Centers for Disease Control and Prevention. Prevalence of disabilities and associated health conditions among adults—United States, 1999. JAMA. 2001; 285(12):1571-1572.
[ii] Cohen SP et al. Sacroiliac Joint pain: A Comprehensive Review of Epidemiology, Diagnosis and Treatment. Expert Rev Neurother. 2013; 13(1):99-116
CONTACT:
Erin Morrison
Tel 952 698 9956
emorrison@zyga.com
View original content with multimedia:http://www.prnewswire.com/news-releases/zyga-announces-highmark-inc-4th-largest-blue-cross-blue-shield-insurer-to-expand-positive-coverage-of-minimally-invasive-si-joint-fusion-300521296.html
SOURCE Zyga Technology, Inc.
